Clinical Trials Sponsored by Facet Biotech

Total 1788 results

Facet Biotech

Completed

Humanized Anti-IL-2 Receptor Monoclonal Antibody in Moderate-to-severe Ulcerative Colitis

Ulcerative Colitis | Inflammatory Bowel Disease | Gastrointestinal Disease

United States, Canada, Belgium
Facet Biotech

Completed

A Humanized Anti-Interferon-γ Monoclonal Antibody (HuZAF) for Moderate to Severe Crohn's Disease

Crohn's Disease | Colitis | Digestive System Disease | Gastrointestinal Disease | Intestinal Disease

United States, Canada
Facet Biotech

Completed

Study of Daclizumab in Patients With Chronic, Persistent Asthma

Asthma

United States
Facet Biotech

Completed

Pilot Study in Patients With Symptomatic Steroid-Naive Asthma

Asthma

United States
Facet Biotech

Completed

Phase I, Multi-Center, Open-Label, Dose Escalation Study of HuLuc63 in Subjects With Advanced Multiple Myeloma

Multiple Myeloma

United States
Facet Biotech

Withdrawn

A Randomized, Double-blinded, Placebo-controlled, Dose-ranging Study of Cardene® I.V. in Pediatric Subjects With Hypertension

Hypertension

United States
Facet Biotech

Completed

Research Study of Visilizumab for Treatment of Acute Graft Versus Host Disease

Graft vs Host Disease

United States
Facet Biotech

Completed

Research Study in Patients With Severe Ulcerative Colitis

Ulcerative Colitis

United States
Facet Biotech

Withdrawn

A Study of Ularitide in the Treatment of Subjects With Acute Decompensated Heart Failure

Heart Failure, Congestive

United States
Facet Biotech
Biogen

Terminated

A Phase 2, Single-Arm Study of Volociximab Monotherapy in Subjects With Platinum-Resistant Advanced Epithelial Ovarian Cancer or Primary Peritoneal Cancer

Peritoneal Neoplasms | Ovarian Cancer

United States, Canada
Rockefeller University
Facet Biotech

Completed

To Study the Effects of CD25 and Low Dose Cyclosporin in the Treatment of Active Psoriasis Vulgaris

Psoriasis

United States
Rockefeller University
Facet Biotech

Completed

To Study the Use of Humanized CD25 in Preventing the Relapse of Psoriasis Vulgaris

Psoriasis

United States
Facet Biotech
PDL BioPharma, Inc.

Completed

Ulcerative Colitis Study: Study of Visilizumab in Patients With Severe Ulcerative Colitis

Severe Ulcerative Colitis

United States
Facet Biotech
PDL BioPharma, Inc.

Completed

Visilizumab for Treatment of Perianal Fistulas in Crohn's Disease

Crohn's Disease

United States
PDL BioPharma, Inc.

Completed

Study of Subcutaneous Daclizumab in Patients With Active, Relapsing Forms of Multiple Sclerosis

Multiple Sclerosis

United States, Canada
PDL BioPharma, Inc.

Terminated

An Observational Follow-up Study for Subjects Receiving Salvage Therapy After Previous Treatment in a Visilizumab Study for Intravenous Steroid-Refractory Ulcerative Colitis

Ulcerative Colitis

Belgium, France, United States, Italy, Australia, Czech Republic, Netherlands, Ireland, Norway, Canada, Austria, Germany, Hungary, Ukraine
Facet Biotech
PDL BioPharma, Inc.

Completed

Visilizumab for Moderate to Severe Inflammatory, Nonstricturing, Nonpenetrating Crohn's Disease

Crohn's Disease

United States
PDL BioPharma, Inc.

Completed

Volociximab in Combination With DTIC in Patients With Metastatic Melanoma Not Previously Treated With Chemotherapy

Melanoma | Metastases

United States
PDL BioPharma, Inc.

Terminated

A Phase 2 Study to Evaluate the Safety, Tolerability, and Activity of Fontolizumab in Subjects With Active Rheumatoid Arthritis

Arthritis, Rheumatoid

United States
Facet Biotech
PDL BioPharma, Inc.

Terminated

A Study of Visilizumab in Subjects With Intravenous Steroid-Refractory Ulcerative Colitis

Ulcerative Colitis

France, Belgium, United States, Israel, Australia, Germany, Netherlands, Austria, Canada, Czech Republic, Ukraine, Norway, Hungary, Slovakia
Facet Biotech
PDL BioPharma, Inc.

Terminated

Study of Visilizumab Versus Placebo in Subjects With Intravenous Steroid-refractory Ulcerative Colitis Previously Responsive in a Visilizumab Study

Ulcerative Colitis

Belgium, France, United States, Italy, Canada, Czech Republic, Norway, Israel, Austria, Croatia, Australia, Hungary, Ukraine, Netherlands, Germany
Facet Biotech
PDL BioPharma, Inc.

Withdrawn

A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Visilizumab in Subjects With Intravenous Steroid-Refractory Ulcerative Colitis

Intravenous Steroid-Refractory Ulcerative Colitis
Facet Biotech
National Cancer Institute (NCI)

Unknown

Combination Chemotherapy With or Without Monoclonal Antibody Therapy in Treating Patients With Refractory or Relapsed Acute Myelogenous Leukemia

Leukemia

United States, Canada, Netherlands, Belgium, Germany, United Kingdom, France
Fred Hutchinson Cancer Center
Facet Biotech

Unknown

Research Study of Visilizumab for Treatment of Glucocorticoid- Refractory Graft Versus Host Disease

Graft-vs-Host Disease

United States
Facet Technologies

Completed

Lancet Blood Volume Comparison Study

Diabetes

United States
Facet Technologies

Completed

Lancing Device Comparison Study

Diabetes Mellitus, Type 2 | Diabetes Mellitus, Type 1
Facet Technologies
LifeScan

Completed

The Characterization of Blood Volumes of Commercially Available Lancing Devices

Diabetes

United States
National Institute of Allergy and Infectious Diseases...
Facet Biotech

Completed

Comparison of Two Methods in the Treatment of Cytomegalovirus of the Eyes in Patients With AIDS

HIV Infections | Cytomegalovirus Retinitis

United States
Theratocular Biotek Co.

Recruiting

A Study to Investigate the Effect on Central Macular Thickness of Treatment With MG-O-1002 Eye Drops in Participants Aged Over 45 With Neovascular Age-related Macular Degeneration (nAMD)

Age-Related Macular Degeneration

Thailand
Sientra, Inc.
Faces+

Recruiting

Autologous Fat Grafting to the Face With Use of the Viality™ System

Adipose Tissue

United States
Indiana University School of Medicine
Roche Pharma AG; Facet Biotech; Pescovitz, Mark D., M.D.

Completed

Prevention of Diabetes Progression Trial (PDPT)

Newly Diagnosed With Type 1 Diabetes

United States
Instituto Portugues da Face

Completed

Comparison of Temporomandibular Joint Arthroscopy With Botulinum Toxin Injection Versus Placebo (ARTHROBTX)

Temporomandibular Joint Disorders

Portugal
Instituto Portugues da Face

Completed

Outcomes of Bilateral Temporomandibular Joint Arthroscopy and the Role of a Second Intervention - Timings and Results

Bilateral Temporomandibular Joint Disorder
YMD Eye and Face

Completed

Split-Face Prospective Study Comparing Botox to Xeomin for the Treatment of Facial Wrinkles

Facial Wrinkles

United States
Instituto Portugues da Face

Enrolling by invitation

Temporomandibular Joint Arthrocentesis With Infiltration of PRP + Ropivacaine Versus PRP

Temporomandibular Joint Disorders

Portugal
Instituto Portugues da Face

Completed

Unilateral TMJ Discectomy Without Interposal Material in Patients With Disc Perforation or Fragmentation

Temporomandibular Disorders

Portugal
Sotio Biotech Inc.
SOTIO Biotech AG; SOTIO Biotech a.s.

Recruiting

BOXR1030 T Cells in Subjects With Advanced GPC3-Positive Solid Tumors (DUET-1)

Hepatocellular Carcinoma | Squamous Cell Carcinoma of the Lung | Merkel Cell Carcinoma | Myxoid/Round Cell Liposarcoma

United States
SOTIO Biotech AG
SOTIO Biotech a.s.

Active, not recruiting

Study of SO-C101 and SO-C101 in Combination With Pembro in Adult Patients With Advanced/Metastatic Solid Tumors

Melanoma | Renal Cell Carcinoma | Cervical Cancer | Hepatocellular Carcinoma | Gastric Cancer | Ovarian Cancer | Non Small Cell Lung Cancer | Mesothelioma | Bladder Cancer | Triple Negative Breast Cancer | Small-cell Lung Cancer | Head and Neck Squamous Cell Carcinoma | Thyroid | Anal Cancer | Merkel Cell Carcinoma | Biliary... and other conditions

United States, France, Spain, Czechia
Impact Biotech Ltd
Impact biotech Ltd.

Not yet recruiting

Padeliporfin VTP Using Robotic Assisted Bronchoscopy in Peripheral Lung Cancer

Peripheral Lung Tumor
Aurion Biotech

Recruiting

A Phase 1/2 Study of AURN001 in Subjects With Corneal Edema Secondary to Corneal Endothelial Dysfunction (ABA-1) (CLARA)

Corneal Edema | Corneal Endothelial Dysfunction

United States, Canada
Meccellis Biotech

Recruiting

Safety and Clinical Performance of a Biological Matrix Used in Implant-based Breast Reconstruction

Breast Reconstruction Following Mastectomy

France
ElsaLys Biotech

Not yet recruiting

Evaluation of EFficacy and SaFEty of Leukotac (Inolimomab) in Pediatric Patients With SR-aGvHD (EiFFEL)

Steroid Refractory GVHD
J2H Biotech

Completed

Phase 1 Study to Investigate Safety, Tolerability, PK/PK of J2H-1702 in Healthy Males

Non-alcoholic Steatohepatitis

Korea, Republic of
CEN Biotech

Completed

Effect of Audistim® Day/Night on Hearing Comfort and Patient Quality of Life of Patients With Chronic Tinnitus. (TINNITY)

Tinnitus

France
Aurion Biotech

Completed

A Safety and Efficacy Study of Corneal Injection for Endothelial Dysfunction Using Human Corneal Endothelial Cell Therapy in Subjects With Corneal Edema Secondary to Endothelial Dysfunction (Escalon)

Corneal Edema

El Salvador
Biotech Dental

Completed

Performance and Safety of Use of the "KONTACT PERIO LEVEL" Transgingival Titanium Dental Implant (KPL)

Tooth Loss | Partially Edentulous Maxilla | Partially Edentulous Mandible

France
Acticor Biotech

Completed

Acute Ischemic Stroke Interventional Study (ACTIMIS)

Acute Ischemic Stroke

France
Oncolytics Biotech

Completed

Study of Pembrolizumab With REOLYSIN® and Chemotherapy in Patients With Advanced Pancreatic Adenocarcinoma

Pancreatic Adenocarcinoma

United States
Cinfa Biotech

Completed

Immunogenicity and Pharmacodynamic of B12019 and Neulasta® in Healthy Subjects

Healthy Volunteers

Germany
Activartis Biotech

Completed

Cancer Immune Therapy for the Treatment of Refractory Solid Tumours of Childhood

Childhood Solid Tumor

Austria

Clinical Trials Sponsored by Facet Biotech

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Japan

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations